443 related articles for article (PubMed ID: 21822447)
1. Acid peptic diseases: pharmacological approach to treatment.
Mejia A; Kraft WK
Expert Rev Clin Pharmacol; 2009 May; 2(3):295-314. PubMed ID: 21822447
[TBL] [Abstract][Full Text] [Related]
2. Acid suppression therapy: where do we go from here?
Scarpignato C; Pelosini I; Di Mario F
Dig Dis; 2006; 24(1-2):11-46. PubMed ID: 16699262
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
Huang JQ; Hunt RH
Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
[TBL] [Abstract][Full Text] [Related]
4. New therapeutic options in the treatment of GERD and other acid-peptic disorders. Based on a presentation by Duane D. Webb, MD, FACG.
Am J Manag Care; 2000 May; 6(9 Suppl):S467-75. PubMed ID: 10977486
[TBL] [Abstract][Full Text] [Related]
5. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases.
Inatomi N; Matsukawa J; Sakurai Y; Otake K
Pharmacol Ther; 2016 Dec; 168():12-22. PubMed ID: 27514776
[TBL] [Abstract][Full Text] [Related]
6. The Effect of H
Shim YK; Kim N
Korean J Gastroenterol; 2017 Jul; 70(1):4-12. PubMed ID: 28728310
[TBL] [Abstract][Full Text] [Related]
7. Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors--overview and clinical implications.
Robinson M
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():1-10. PubMed ID: 15496213
[TBL] [Abstract][Full Text] [Related]
8. Historical impact to drive research in peptic ulcer disease.
Banić M; Malfertheiner P; Babić Z; Ostojić R; Kujundzic M; Fatović-Ferenčić S; Plesko S; Petričušić L
Dig Dis; 2011; 29(5):444-53. PubMed ID: 22095008
[TBL] [Abstract][Full Text] [Related]
9. Overview of pharmacologic agents for acid suppression in critically ill patients.
Welage LS
Am J Health Syst Pharm; 2005 May; 62(10 Suppl 2):S4-S10. PubMed ID: 15905600
[TBL] [Abstract][Full Text] [Related]
10. Current status of acid pump antagonists (reversible PPIs).
Wurst W; Hartmann M
Yale J Biol Med; 1996; 69(3):233-43. PubMed ID: 9165692
[TBL] [Abstract][Full Text] [Related]
11. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
Clissold SP; Campoli-Richards DM
Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents.
Sanders SW
Clin Ther; 1996; 18(1):2-34; discussion 1. PubMed ID: 8851451
[TBL] [Abstract][Full Text] [Related]
13. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials.
Scally B; Emberson JR; Spata E; Reith C; Davies K; Halls H; Holland L; Wilson K; Bhala N; Hawkey C; Hochberg M; Hunt R; Laine L; Lanas A; Patrono C; Baigent C
Lancet Gastroenterol Hepatol; 2018 Apr; 3(4):231-241. PubMed ID: 29475806
[TBL] [Abstract][Full Text] [Related]
14. New molecular targets for treatment of peptic ulcer disease.
Lehmann F; Hildebrand P; Beglinger C
Drugs; 2003; 63(17):1785-97. PubMed ID: 12921485
[TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review.
Yang M; He M; Zhao M; Zou B; Liu J; Luo LM; Li QL; He JH; Lei PG
Curr Med Res Opin; 2017 Jun; 33(6):973-980. PubMed ID: 28076696
[TBL] [Abstract][Full Text] [Related]
16. Optimal use of proton pump inhibitors for treating acid peptic diseases in primary care.
Tack J; Louis E; Persy V; Urbain D
Acta Gastroenterol Belg; 2013 Dec; 76(4):393-402. PubMed ID: 24592542
[TBL] [Abstract][Full Text] [Related]
17. Intravenous proton pump inhibitors for peptic ulcer bleeding: Clinical benefits and limits.
Cheng HC; Sheu BS
World J Gastrointest Endosc; 2011 Mar; 3(3):49-56. PubMed ID: 21455342
[TBL] [Abstract][Full Text] [Related]
18. Critical issues in the pathophysiology and management of peptic ulcer disease.
Hunt RH; Malfertheiner P; Yeomans ND; Hawkey CJ; Howden CW
Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):685-99. PubMed ID: 8590166
[TBL] [Abstract][Full Text] [Related]
19. Etiopathogenetic principles and peptic ulcer disease classification.
Tytgat GN
Dig Dis; 2011; 29(5):454-8. PubMed ID: 22095009
[TBL] [Abstract][Full Text] [Related]
20. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
de Korwin JD; Ducrotté P; Vallot T
Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
